Dr David Chan, a medical oncologist, has been a Sydney Vital member for over three years. David is especially interested in the area of NETs, uncommon tumours marked by significant heterogeneity in clinical course and prognosis.
Dr Andrew Care has been a member of Sydney Vital since 2017 and this year was awarded a 2018 Early Career Fellowship from the Cancer Institute NSW.
On the August 9, 2018, Sydney Vital teamed up with The Unicorn Foundation to host the 2018 Neuroendocrine Tumour Q&A Session. The session saw over 100 attendees come together to hear about what’s new in Neuroendocrine Tumours and why research plays a vital role in patient outcomes.
The annual NSW Premier’s Awards are back.
Hosted by the Cancer Institute NSW, this year the Awards will recognise the achievements of individuals and teams that work in cancer research across NSW and showcase the outstanding work they have put in to lessen the impact of cancer.
We are extremely proud of one of our researchers, Professor Anthony Gill who has been honoured in the Queen’s Birthday list. For his significant service to medical research in the field of surgical pathology as an academic, author, adviser and mentor, he has been appointed a Member of the Order of Australia (AM).
Prof Gill is a surgical pathologist, his research focuses on hereditary cancer syndromes, endocrine pathology and gastrointestinal pathology with a special emphasis on pancreaticobiliary pathology.
See the full Queen’s Birthday 2018 Honours list here.
Sydney Vital and The Hepato-Pancreato-Biliary (HPB) Unit at Royal North Shore Hospital are offering a full time scholarship for a Doctor of Philsophy (Medicine) student at the University of Sydney commencing 2017 or 2018.
1. Applicants must have an unconditional offer of admission for full-time studies in the Doctor of Philophy (Medicine) program at the University of Sydney commencing 2017 or 2018.
2. Applicants must be willing to undertake research in a field of research that includes, but is not limited to:
– Prognostic biomarkers in pancreatic cancer-IHC, proteomics, metabolomics
– Role of pancreatitis in adverse outcomes following pancreatic surgery
– Neo-adjuvant chemotherapy in resectable pancreatic cancer
– Nutrition and quality of life in pancreatic cancer or Immune therapy in pancreatic cancer
3. Applicants must hold a Honours degree (First Class or Second Class Upper) and/or a medical degree recognised in Australia.
4. Applicants must be Australian citizens, Australian permanent residents, New Zealand citizens or international applicants eligible for a visa.
Value: $35,000 per annum
Duration: For up to one year, subject to satisfactory academic performance. The recipient may apply for an extension and this may be available if funds are available.
Open Date: Apply Now
Close Date: 2 December
For more information, please visit
A/Prof Rory Clifton-Bligh (along with co-chair Dr Judith Favier [France]) will be hosting the 5th International Symposium on Phaeochromocytoma and Paraganglioma (Sofitel Sydney Wentworth) from 30 August to 2 September 2017. The meeting brings together international and national thought leaders and will showcase the latest research, new preclinical models, new predisposition genes, new metabolomic studies, new genetic triggers for malignancy, and a comprehensive approach to state-of-art clinical management. The program also includes patient focused sessions, with the aim of bringing patients and physicians together to tackle the clinical issues of greatest difficulty and concern. For those with an interest in endocrinology, endocrine/head and neck surgery, oncology, hypertension, nuclear physics, genetics and basic research, further information (including program and registration details) can be found here.
Prof Stan Sidhu (Professor of Surgery, Head of the University of Sydney Endocrine Surgical Unit) and his team have conducted a clinical trial; A study of EnGeneIC Dream Vectors (EDV’s) packaged with the chemotherapy PNU-159682, given simultaneously as non-targeted EDVs carrying an immune enhancer called EDVs40-mer, in participants with advanced cancer who have no curative treatment options.
Trail ID: ACTRN12617000037303